2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1933

M2 Macrophage Is the Predominant Phenotype in Airways Inflammatory Lesions in Patients with Granulomatosis with Polyangiitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1462

Magnesium Is a New Mediator Arthritis Severity and Joint Damage

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1306

Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1595

Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1601

Maintenance Treatment Using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – a Prospective, Multicentered, Single Arm Clinical Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1188

Major Comorbidities of Idiopathic Inflammatory Myositis: A Population-Based Study Using 10 Years of Follow up from the National Health Insurance in Korea

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1573

Major Histocompatibility Antigen HLA-DQ6.1 (DQA1*0103/DQB1*0601) Increases Rheumatoid Arthritis Risk Independent of Shared Epitope Among Indians

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1953

Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1310

Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1616

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1255

Medicare Part B Utilization By Rheumatology Health Care Providers As Related to Population Demographics from 2013

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1402

Meeting the Needs of Adolescents with Autoimmune Diseases, the Development of a Clinical Transition Pathway

Pediatric Rheumatology – Clinical and Therapeutic Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1869

Mental Health Care in Systemic Sclerosis; Rates of Utilization and Associated Factors in the Scleroderma Patient-Centered Intervention Network Cohort

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1141

Mentoring the Pediatric Rheumatology Community through the American College of Rheumatology/Childhood Arthritis and Rheumatology Research Alliance Mentoring Interest Group Network: A Five-Year Status Update

Education - Poster

9:00AM-11:00AM: Abstract Number: 1844

Mesenchymal Stem Cells Ameliorate the Deficiencies in Immunomodulatory and Phagocytic Capacities of Lupus Macrophages

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].